Cortistatin 14, human, rat

CAS No. 193829-96-8

Cortistatin 14, human, rat( CST-14, human, rat )

Catalog No. M29887 CAS No. 193829-96-8

Cortistatin 14 is a somatastatin-like neuropeptide with neuronal depressant and sleep modulating properties. Cortistatin 14 is present primarily in the cortex and hippocampus.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Cortistatin 14, human, rat
  • Note
    Research use only, not for human use.
  • Brief Description
    Cortistatin 14 is a somatastatin-like neuropeptide with neuronal depressant and sleep modulating properties. Cortistatin 14 is present primarily in the cortex and hippocampus.
  • Description
    Cortistatin 14 is a somatastatin-like neuropeptide with neuronal depressant and sleep modulating properties. Cortistatin 14 is present primarily in the cortex and hippocampus.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CST-14, human, rat
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    193829-96-8
  • Formula Weight
    1721.01
  • Molecular Formula
    C81H113N19O19S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:{Pro}{Cys}{Lys}{Asn}{Phe}{Phe}{Trp}{Lys}{Thr}{Phe}{Ser}{Ser}{Cys}{Lys} (Disulfide bridge: Cys2-Cys13)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Jiang J, et al. Centrally Administered Cortistation-14 Induces Antidepressant-Like Effects in Mice via MediatingGhrelin and GABAA Receptor Signaling Pathway. Front Pharmacol. 2018 Jul 19;9:767.
molnova catalog
related products
  • Lucidenic acid M

    Lucidenic acid M

  • WDR5-0102

    WDR5-0102 is a compound that inhibits the WDR5-MLL1 interface (K dis = 7 μM, K d = 4 μM), selectively reducing MLL1 HMT activity without affecting the human H3K4 methyltransferase SETD7 or other HMTs, including G9a, EHMT1, SUV39H2, SETD8, PRMT3, and PRMT5.

  • Transforming Growth ...

    Transforming Growth Factor β1 Peptide, TGF - β1 (60 - 66), amide